Literature DB >> 3121520

Protective effect of an outer membrane vaccine against Pseudomonas aeruginosa infection.

B U von Specht1, G Strigl, W Ehret, W Brendel.   

Abstract

The outer membrane proteins, F, H2 and I, from PA12 strain of Pseudomonas aeruginosa, were purified and used successfully for immunization of Balb/c mice. The immunized mice were protected against challenge with a 2-26 fold LD50 of all known 19 serogroups of P. aeruginosa.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3121520     DOI： 10.1007/bf01647755

Source DB:  PubMed          Journal:  Infection        ISSN： 0300-8126            Impact factor:   3.553


  9 in total

1.  Electrophoretic resolution of the "major outer membrane protein" of Escherichia coli K12 into four bands.

Authors:  B Lugtenberg; J Meijers; R Peters; P van der Hoek; L van Alphen
Journal:  FEBS Lett       Date:  1975-10-15       Impact factor: 4.124

2.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.

Authors:  H Towbin; T Staehelin; J Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1979-09       Impact factor: 11.205

3.  A simplification of the protein assay method of Lowry et al. which is more generally applicable.

Authors:  G L Peterson
Journal:  Anal Biochem       Date:  1977-12       Impact factor: 3.365

4.  Controlled trials of a polyvalent pseudomonas vaccine in burns.

Authors:  R J Jones; E A Roe; J L Gupta
Journal:  Lancet       Date:  1979-11-10       Impact factor: 79.321

5.  Pseudomonas aeruginosa bacteremia: susceptibility of 100 blood culture isolates to seven antimicrobial agents and its clinical significance.

Authors:  A L Baltch; M Hammer; R P Smith; N Sutphen
Journal:  J Lab Clin Med       Date:  1979-08

6.  Isolation and characterization of major outer membrane proteins of Pseudomonas aeruginosa strain PAO with special reference to peptidoglycan-associated protein.

Authors:  T Mizuno; M Kageyama
Journal:  J Biochem       Date:  1979-10       Impact factor: 3.387

7.  Use of a purified outer membrane protein F (porin) preparation of Pseudomonas aeruginosa as a protective vaccine in mice.

Authors:  H E Gilleland; M G Parker; J M Matthews; R D Berg
Journal:  Infect Immun       Date:  1984-04       Impact factor: 3.441

8.  A new polyvalent pseudomonas vaccine.

Authors:  P Merle; L Robbel; K D Hungerer
Journal:  Behring Inst Mitt       Date:  1984-11

9.  Outer membrane proteins of Pseudomonas aeruginosa serotype strains.

Authors:  L M Mutharia; T I Nicas; R E Hancock
Journal:  J Infect Dis       Date:  1982-12       Impact factor: 5.226
  9 in total
  10 in total

1.  Sequence and transcriptional start site of the Pseudomonas aeruginosa outer membrane porin protein F gene.

Authors:  M Duchêne; A Schweizer; F Lottspeich; G Krauss; M Marget; K Vogel; B U von Specht; H Domdey
Journal:  J Bacteriol       Date:  1988-01       Impact factor: 3.490

2.  Protection against experimental Pseudomonas aeruginosa infection by recombinant P. aeruginosa lipoprotein I expressed in Escherichia coli.

Authors:  M Finke; M Duchêne; A Eckhardt; H Domdey; B U von Specht
Journal:  Infect Immun       Date:  1990-07       Impact factor: 3.441

3.  Treatment of infections in patients with cystic fibrosis.

Authors:  M I Marks
Journal:  Infection       Date:  1987       Impact factor: 3.553

4.  Pseudomonas aeruginosa outer membrane lipoprotein I gene: molecular cloning, sequence, and expression in Escherichia coli.

Authors:  M Duchêne; C Barron; A Schweizer; B U von Specht; H Domdey
Journal:  J Bacteriol       Date:  1989-08       Impact factor: 3.490

5.  Protection of immunosuppressed mice against infection with pseudomonas aeruginosa by monoclonal antibodies to outer membrane protein OprI.

Authors:  R Rahner; A Eckhardt; M Duchêne; H Domdey; B U von Specht
Journal:  Infection       Date:  1990 Jul-Aug       Impact factor: 3.553

6.  Protection of immunosuppressed mice against infection with Pseudomonas aeruginosa by recombinant P. aeruginosa lipoprotein I and lipoprotein I-specific monoclonal antibodies.

Authors:  M Finke; G Muth; T Reichhelm; M Thoma; M Duchêne; K D Hungerer; H Domdey; B U von Specht
Journal:  Infect Immun       Date:  1991-04       Impact factor: 3.441

7.  Safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers.

Authors:  E Mansouri; J Gabelsberger; B Knapp; E Hundt; U Lenz; K D Hungerer; H E Gilleland; J Staczek; H Domdey; B U von Specht
Journal:  Infect Immun       Date:  1999-03       Impact factor: 3.441

8.  Protection of immunocompromised mice against lethal infection with Pseudomonas aeruginosa by active or passive immunization with recombinant P. aeruginosa outer membrane protein F and outer membrane protein I fusion proteins.

Authors:  B U von Specht; B Knapp; G Muth; M Bröker; K D Hungerer; K D Diehl; K Massarrat; A Seemann; H Domdey
Journal:  Infect Immun       Date:  1995-05       Impact factor: 3.441

9.  TH1 cells trigger tumor necrosis factor alpha-mediated hypersensitivity to Pseudomonas aeruginosa after adoptive transfer into SCID mice.

Authors:  R Früh; B Blum; H Mossmann; H Domdey; B U von Specht
Journal:  Infect Immun       Date:  1995-03       Impact factor: 3.441

Review 10.  Understanding Pseudomonas aeruginosa-Host Interactions: The Ongoing Quest for an Efficacious Vaccine.

Authors:  Maite Sainz-Mejías; Irene Jurado-Martín; Siobhán McClean
Journal:  Cells       Date:  2020-12-05       Impact factor: 6.600
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.